Nitrogen-Based Heterocyclic Compounds: A Promising Class of Antiviral Agents against Chikungunya Virus

Andreza C. Santana 1,†, Ronaldo C. Silva Filho 1,‡, José C. J. M. D. S. Menezes 2,3,*,†, Diego Allonso 4,*,‡ and Vinicius R. Campos 1,*,‡

1 Departamento de Química Orgânica, Campus do Valonguinho, Instituto de Química, Universidade Federal Fluminense, Niterói, Rio de Janeiro 24020-141, Brazil; andrezasantana@id.uff.br (A.C.S.); ronaldocouto@id.uff.br (R.C.S.F.)
2 Section of Functional Morphology, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 859-3298, Japan
3 Research & Development, Esteem Industries Pvt. Ltd., Bicholim, Goa 403 529, India
4 Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil
* Correspondence: josemenezes@ua.pt (J.C.J.M.D.S.M.); diegoallonso@pharma.ufrj.br (D.A.); viniciuscampos@id.uff.br (V.R.C.)
† These authors equally contributed to this article.
‡ These authors equally contributed to this work and are co-senior authors.

Abstract: Arboviruses, in general, are a global threat due to their morbidity and mortality, which results in an important social and economic impact. Chikungunya virus (CHIKV), one of the most relevant arbovirus currently known, is a re-emergent virus that causes a disease named chikungunya fever, characterized by a severe arthralgia (joint pains) that can persist for several months or years in some individuals. Until now, no vaccine or specific antiviral drug is commercially available. Nitrogen heterocyclic scaffolds are found in medications, such as aristeromycin, favipiravir, fluorouracil, 6-azauridine, thioguanine, pyrimethamine, among others. New families of natural and synthetic nitrogen analogous compounds are reported to have significant anti-CHIKV effects. In the present work, we focus on these nitrogen-based heterocyclic compounds as an important class with CHIKV antiviral activity. We summarize the present understanding on this class of compounds against CHIKV and also present their possible mechanism of action.

Keywords: nitrogen heterocyclic; Chikungunya virus; antiviral; arboviruses

1. Introduction

Mosquito-borne viruses represent a serious health problem worldwide due to a number of factors, including the vectors’ growing geographic expansion and the easy mobility of humans across all continents, which culminates in a perfect scenario for virus propagation [1]. Among the arboviruses that cause human disease, Chikungunya virus (CHIKV) is one of the most relevant, mainly because of its great social and economic impact resultant from its high morbidity, although it is rarely associated with death. It was first isolated in the 1950s in the region currently known as Tanzania, and since then has been responsible for some sporadic outbreaks in the African and Asian continents [2]. CHIKV is transmitted by mosquitoes of the genus Aedes spp., most commonly by Aedes aegypti and Aedes albopictus [3].

The adaptation of CHIKV to replicate in Aedes albopictus has expanded its spread around the world, resulting in outbreaks not only in Africa and Southeast Asia, but in other continents such as Europe (mainly in Italy and France) and in the Americas [4]. In the Americas, the first CHIKV outbreak was reported in 2013 on the Caribbean island of Saint Martin, which resulted in more than 1.2 million cases [5]. Since then, other countries such as Brazil, have documented persistent outbreaks of CHIKV. In the second half of 2020 alone,
approximately 81,000 cases of chikungunya fever have been reported across the Americas, and 97% of the cases were in Brazil [6,7].

CHIKV is a member of the *Togaviridae* family and of the *Alphavirus* genus, and is contained in the Semliki forest antigenic complex, which has other alphaviruses, such as: Ross River, O’nyong-nyong, Getah, Bebaru, Semliki forest, and Mayaro viruses, which are endemic in South America [7]. Clinical symptoms are observed in almost all infected individuals and more than half of the patients have persistent polyarthritis, which might last several months or years after the acute viral infection [8].

Despite causing morbidity, there is no therapeutic treatment available on the market against CHIKV. Some compounds with a broad antiviral activity such as ribavirin, harringtonine, and interferon-alfa (IFN-α) showed great efficiency against CHIKV only in vitro [9]. On the other hand, the use of chloroquine exhibited a dose-dependent and time-dependent inhibitory effect on CHIKV replication in vitro, but clinical studies have failed to prove its effectiveness in infected patients [10,11].

In clinical practice, treatment is strictly limited to symptom relief, with the use of antipyretics, analgesics, corticosteroids, and non-steroidal anti-inflammatory drugs. In some patients with severe arthralgia and polyarthritis, the administration of methotrexate and sulfasalazine which are called disease modifying anti-rheumatic drugs, is necessary [12].

Therefore, it becomes clear that there is an urgency and a necessity to discover new classes of compounds that can be used in clinics to treat CHIKV infection. In the search for new candidates with anti-CHIKV activity, nitrogen-based heterocyclic derivatives, such as pyrimidine, pyrazine, and purine, have emerged as promising compounds. Scientific literature points to a very interesting potential of these scaffolds against CHIKV infection therapy. Therefore, this work aims to review the existing literature for natural and synthetic nitrogen-based heterocyclic derivatives and their potential CHIKV antiviral activity.

2. CHIKV Infection

CHIKV has a single-strand, positive-polarity RNA genome, whose size varies between 9.7 and 12 kb [13]. The viral particles, which are often spherical, have a diameter of 70 nm and an isometric nucleocapsid of 40 nm [14]. The proteins are encoded by two open reading frames (ORFs) in which the first two-thirds of the genome from the 5’ end is responsible for expression of the non-structural proteins (NSPs) named nsP1, nsP2, nsP3, and nsP4; whereas the last one-third located at the 3’ end codifies a subgenomic RNA that originates from three structural proteins and two peptides: capsid (C), enveloped glycoprotein 1 (E1), glycoprotein enveloped 2 (E2), E3, and 6K [1,15,16].

Glycoproteins E1 and E2, which form heterodimers, are found on the viral surface and are involved in the target cell recognition [10,12,17]. After interaction with a specific receptor in the cell membrane, the virus particle undergoes endocytosis in vesicles covered by clathrins. The pH acidification in the endosome causes a tridimensional rearrangement of the E1 subunit culminating in the exhibition of the fusion peptide, which will be responsible for the fusion of the envelope with the endosomal membranes and the consequent release of the nucleocapsid to the cytoplasm. Thereafter, the RNA genome gets exposed, and translation of NSPs begins. These NSPs are responsible for the replication complex assembly and perform all the steps necessary for successful virus replication. It is important to highlight that the NSPs are translated as a polyprotein that are further processed as nsP1, nsP2, nsP3, and nsP4 by the action of the viral protease nsP2 [10,13].

The nsP1 manages the enzymatic activities of guanine-7-methyltransferase and guanylyltransferase. It is also associated with membranes and probably acts as a scaffold to attach the viral replication complex (non-structural proteins) to the host membranes. The capping of viral genomes is critical because it has its importance in translating proteins from genomic and subgenomic RNAs, making it a potential target for antiviral drugs because it is specific and less prone to side effects [11,18,19].

NsP2 has the following enzymatic functions: RNA helicase, nucleoside triphosphatase (NTPase), and RNA-dependent RNA-triphosphatase-5’RNA activity, despite its protease
activity. This protein is essential for viral viability [16,20]. The nsP3 macrodomain acts as part of the replicase unit and is present in RNA synthesis. It is subdivided into three domains: N-terminal that connects with negatively charged polymers, the one unique to alphavirus (AUD) and hypervariable C-terminal (HVR), which are responsible for the metabolism of the ADP ribose derivatives, which regulate functions in the cell. NsP4 acts as an RNA-dependent RNA polymerase that synthesizes new viral RNAs from the pre-existing RNA genome [3,12,18,21].

The lack of proofreading activity of the nsP4, which is responsible for high mutation rates [22], in association with the A226V substitution at E1 protein, may be related to a greater virus virulence and allow its best adaptation to replicate in Aedes albopictus mosquitoes, which explains the rapid spread of the disease between 2004 and 2010 to many countries around the Indian Ocean [23]. To date, four CHIKV genotypes have been described: Asian, East Indian, West African, and East/Central/South African. The Asian genotype was first detected in the Caribbean region in late 2013 and then spread throughout Central America [14].

3. Overview of CHIKV Drugs and the Versatility of Nitrogen-Based Heterocycles Derivatives

The ideal treatment of CHIKV-infected patients needs a safe, specific, and efficient antiviral drug that could both eliminate viral replication and block systemic and joint inflammation due to viral infection. Drugs commercially available for other diseases including fever-like illnesses are often used to manage CHIKV symptoms, such as orlistat, chloroquine, favipiravir, arbidol, and ribavirin. However, due to lack of specificity of these drugs against CHIKV infection, they fail to promote complete viral clearance and abrogate its clinical manifestation [8].

The development of a wide spectrum antiviral drugs against different arboviruses, including CHIKV, was for a long time encouraged by the fact they share several mechanisms of pathogenicity. In practice, this strategy has proven quite challenging, since each virus has different cell tropism, which elicits distinct inflammatory responses, as well as promotes different mechanisms of immune evasion. The structural and functional diversity of viral enzymes often used as pharmacological targets, such as the RNA-dependent RNA polymerase (nsP4) and protease (nsP2), significantly alters the affinity and activity of polymerase or protease inhibitors, respectively, which, in the end, drives the antiviral development to a virus-specific pathway [10,13,24–30].

Therefore, finding potent and efficient antivirals with novel scaffolds that have the potential to specifically interact and impair viral enzymatic activities of a single viral family or viral genus is the pursued path toward successful drug development. In this context, the nitrogen-based heterocyclic analogs are an important class of organic compounds that have a privileged position. They are a valuable source for therapeutic agents, which is corroborated by the increasing attention received by these compounds over the last decades. Among them, pyrimidine and its derivatives have received great attention due to their biological and pharmacological activities against viral infection, such as aristeromycin (1) and favipiravir (2); as well as anticancer drug, such as fluorouracil (3), thioguanine (4), and azauridine (5); and as antiprotozoal drugs, such as pyrimethamine (6) (Figure 1). Moreover, this class of molecules is usually reported as being druggable and safe for human use, which makes it more attractive for further development. Therefore, in the present review, we will summarize natural and synthetic nitrogen-based heterocycles and their derivatives with reported anti-CHIKV activity [9,11,19,25,31–39] and explore the potential of these molecules as an interesting class for antiviral drug development.
Figure 1. Nitrogen-based heterocycles derivatives with different biological activities.

3.1. Nitrogen Heterocycle–Coumarin Hybrid Compounds

Several natural compounds based on herbs and plant extracts were investigated for activity against CHIKV [40,41]. Among natural products, coumarin has gained much attention due to its pharmacological properties against several diseases. Coumarins with biological activities can be found in various parts of the plant, as seeds, leaves, and roots and also in distinct plant families, such as Apiaceae, Rutaceae, Clusiaceae, and Umbelliferae [42]. Natural coumarin derivatives have been described as having anticoagulant [43], antibacterial, antioxidant, and anticancer properties [44].

Coumarin has been known to play an incremental role in targeting various cell pathways, inhibiting growth and replication, among other targets for a wide range of viruses. The anti-influenza activity of coumarin derivatives was associated with neuraminidase's inhibition of the viral envelope protein [45]. In the case of the human immunodeficiency virus (HIV), coumarin analogs, isomesuol and mesuol (extracted from Marila pluricostata), could act via the phosphorylation of p65 (NF-kB) [46]. While in the hepatitis C virus (HCV), coumarins could act against its replication, increasing the interferon-mediated antiviral responses [47]. The activity of coumarins against dengue virus (DENV) has already been reported, but its mechanisms of action requires further investigation; however, initial studies point to the NS2B/NS3 complex as a possible coumarin target [48]. The activity of coumarin against CHIKV is still under investigation [42,49–53].

In Figure 2, we have summarized some coumarin–nitrogen-based heterocyclic derivatives that were reported to have anti-CHIKV activity. Compounds 7, 8, 11, 14 and 16 were the most potent inhibitors, with EC<sub>50</sub> values ranging from 10.2 to 19.1 μM (concentration necessary to reduce 50% of viral infection in Vero cells), and with a selectivity index (SI) around 5.6 and 11.5 (Table 1). The calculation of the molecular lipophilicity quantified by logP is a major determinant for the absorption of the compound, distribution in the body, penetration through biological barriers, metabolism and excretion (ADME). An ideal logP range is generally between 0.4 and 5.0. Higher values are indicative of malabsorption or permeation of the components. For these pyrimidine–coumarin hybrids, the logP values remained in the range from 2.74 to 3.57 [34,36].

With respect to the benzenesulfonyl ring on coumarin, the para-methyl group at 8, increased the potency and SI value when compared to that of the unsubstituted derivatives 7. The same correlation can be done with nitro compound 11 that increased activity by 2 times, approximately, compared to the 4-position for the same substituent in 10. While for pyrimidine analogs, 12–16, the nitro group at 2-position on the benzenesulfonyl ring on coumarin showed the best activity. Overall, the quinazoline derivatives, 7–11, were more active than the pyrimidine analogs, 12–16, whose logP values are directly proportional to the activity presented 8 > 13 > 15 and 11 > 14 > 16 (Table 1). The presence of hydrophobic substituents at the 5 and 6 position of pyrimidine nucleus (7–11) was an important synthetic
strategy, conferring greater activities against CHIKV and other viruses, such as HIV and HCV [34].

A series of thioguanine-coumarins derivatives were studied, and the methoxylated coumarins [54] (21, 22 and 23) exhibited the best activities against CHIKV compared to the benzouracil coumarins (9–19). EC50 values were below 13.9 \( \mu \text{M} \) with a significant selectivity window covering SI values between 9.37 and 21.7, whereas the molecular lipophilicity of 20, 21, 22 and 23 were between 2.97 and 3.77. The replacement of the coumarinyl (21) by naphthyl group (23) resulted in no significant influence in the EC50 value, probably because of the similar size and planarity of the two substituents. In contrast, substitution of the naphthyl to benzyl (not shown) considerably decreased the EC50 values [54], confirming the importance of the size and planarity of the substituents for proper antiviral activity [54].

![Figure 2. Nitrogen heterocycle–coumarin hybrid with potential activity against Chikungunya virus (CHIKV).](image)

Table 1. Anti-CHIKV activities of the nitrogen heterocycle–coumarin hybrid in the CHIKV 899 strain.

| Reference     | Compound | CC50 (\( \mu \text{M} \)) | EC50 (\( \mu \text{M} \)) | SI   | LogP |
|---------------|----------|-----------------------------|-----------------------------|------|------|
| Hwu (2015) [34] | 7        | 178                         | 19.1                        | 9.3  | 1.91 |
|               | 8        | 117                         | 10.2                        | 11.5 | 2.13 |
|               | 9        | 30                          | 18.4                        | 1.6  | ND   |
|               | 10       | 117                         | 54.5                        | 2.2  | ND   |
|               | 11       | 144                         | 17.2                        | 8.8  | −1.07|
|               | 12       | 126                         | 58                          | 2.2  | ND   |
|               | 13       | 114                         | 26.4                        | 4.3  | 0.611|
|               | 14       | 107                         | 19.0                        | 5.6  | −2.60|
|               | 15       | 60.2                        | 23.1                        | 2.6  | 0.467|
|               | 16       | 75.2                        | 13.0                        | 5.8  | −2.74|
|               | 17       | 104                         | 45.1                        | 2.3  | ND   |
|               | 18       | 13.8                        | 4.6                         | 3.0  | ND   |
|               | 19       | >284                        | 192                         | >1.5 | 1.32 |
| Hwu (2019) [54] | 20       | 81.3                        | 40.9                        | 1.98 | 3.22 |
|               | 21       | >212                        | 9.9                         | >21.7| 3.01 |
|               | 22       | 96.5                        | 10.3                        | 9.37 | 2.97 |
|               | 23       | >227                        | 13.9                        | >16.3| 3.77 |
| Standard: 3-[(methylthio)methyl]coumarin | ND | >485 | ND | - |

EC50 is the concentration of a substance that gives half-maximal response (efficacy); CC50 is the extract concentration of a substance that reduces the cell viability by 50%; SI is the selectivity index.
3.2. Aristeromycin Analogs

The purine analog, aristeromycin, is a naturally occurring molecule found in filamentous bacteria of the species *Streptomyces citricolor*. It provided potent activity against CHIKV, but its high cytotoxicity limited its therapeutic use [35,36]. Mechanistically, aristeromycin has been described as an inhibitor of the hydrolase S-adenosyl-L-homocysteine (SAH), which can also indirectly inhibit the activity of methyl transferases (MTase), which are responsible for capping the viral mRNA. Similar activity in CHIKV is mediated by the nsP1 protein [35].

Therefore, D-6′-fluorinated-aristeromycin analogs (Figure 3) were designed to assess the inhibition of the human SAH and correlate the potential antiviral activity against CHIKV by a probable inhibition of nsP1. It was found that the 6-amino-purines (24, 25, 26) showed interesting results for SAH inhibition or for anti-CHIKV activity when compared with aristeromycin and also with other purines (27 and 28), pyrimidines (29–33), and phosphoramidates (34, 35, 36) as summarized in Table 2.

![Figure 3. Aristeromycin analogs designed for antiviral activity against CHIKV.](image)

These data confirmed the antiviral activity against CHIKV and also suggested that the observed activity may be due to an indirect effect on the activity of nsP1. Compound 26 was one of the most potent inhibitors for SAH (Table 2). Although compound 26 was less toxic than aristeromycin, substantial cytotoxicity, indicated that further adjustments were necessary prior to in vivo and human tests [36].

Among phosphoramidates, which were selectively designed to inhibit virus replication through the binding on the viral polymerase, compound 34 showed the best efficacy and broad-spectrum activity against CHIKV, Middle East respiratory syndrome–coronavirus (MERS-CoV), severe acute respiratory syndrome–coronavirus (SARS-CoV), and Zika virus (ZIKV) but failed in terms of toxicity [36].

The cytotoxicity of the compounds 26 and 34 is explained by their ability to be phosphorylated at 5′, acting as a nucleoside analog that interacts with both viral and host RNA polymerases blocking their activity or preventing host RNA elongation. For this reason, homoaristeromycin analogs with 5′ hydroxyl displacement susceptible to the phosphate transfer zone in kinases were developed. This family of compounds has the advantage of preventing 5′-phosphorylation by cell kinases, maintaining inhibitory activity in relation to SAH. Since the cytotoxicity of compound 1 can be attributed to 5′-phosphorylation, which occurs in the biological environment. Among the compounds of this family, derivative 37 stands out due to its high inhibition of SAH (IC₅₀ = 0.36 μM), as well as its good inhibitory activity against CHIKV (EC₅₀ = 0.12 μM) and low cytotoxicity (CC₅₀ > 250 μM) [35].

Compound 38, unlike 37, showed similar levels of SAH inhibition (IC₅₀ = 0.37 μM) but failed to block viral infection. This result sheds light on the direct role of aristeromycin and its analog on viral nsP1. Kovacikova and collaborators [23] figured out that combined mutations G230R and K299E in the CHIKV nsP1 conferred resistance to 6′-fluoro-
homoneplanocin A (FHNA) and 6′-β-fluoro-homoaristeromycin (FHA). Moreover, in vitro enzymatic analyses with purified and active nsP1 from the alphavirus Semiliki Forest virus indicated that the oxidized (3′-keto) form of FHNA, obtained under nonreducing conditions and in the presence of NAD⁺, can directly inhibit nsP1 MTase activity. Together, these results confirmed that aristeromycin analogs might act directly on the nsP1 MTase activity, rather than just through an indirect effect on the host SAH hydrolase. In addition, the replacement of NH₂ (37) by NHMe (38) significantly decreased its antiviral activity, suggesting that this region of the molecule was very important for the nsP1 inhibitory activity [35].

Table 2. Antiviral activity of the aristeromycin analogs against CHIKV-LS3 [35,36].

| Reference          | Compound | SAH Hydrolase IC₅₀ (μM) | CC₅₀ (μM) | EC₅₀ (μM) | SI |
|--------------------|----------|-------------------------|-----------|-----------|----|
| Standard (1)       | 1.32     | 6.3                     | 0.8       | 7.9       |    |
| Yoon (2019) [36]   |          |                         |           |           |    |
| 24                 | 0.37     | >100                    | >100      | ND        |    |
| 25                 | 9.70     | 1.32                    | 0.53      | 2.49      |    |
| 26                 | 1.06     | >1.25                   | 0.13      | >9.6      |    |
| 27                 | 4.39     | >100                    | >100      | ND        |    |
| 28                 | 0.76     | >100                    | >100      | ND        |    |
| 29                 | >100     | >100                    | >100      | ND        |    |
| 30                 | >100     | >100                    | >100      | ND        |    |
| 31                 | >100     | >100                    | >100      | ND        |    |
| 32                 | >100     | >100                    | >100      | ND        |    |
| 33                 | >100     | >100                    | >100      | ND        |    |
| 34                 | >100     | >12.5                   | 1.95      | >6.4      |    |
| 35                 | >100     | >100                    | >100      | ND        |    |
| 36                 | >100     | >100                    | >100      | ND        |    |
| Shin (2020) [35]   |          |                         |           |           |    |
| 37                 | 0.36     | >250                    | 0.12      | ND        |    |
| 38                 | 0.37     | >100                    | >100      | ND        |    |
| 39                 | >100     | >100                    | >100      | ND        |    |
| 40                 | 2.03     | >25                     | >100      | ND        |    |
| 41                 | 3.05     | >100                    | >100      | ND        |    |

IC₅₀ is the concentration of a substance that inhibited 50% of replication.

3.3. Ribonucleoside Derivatives

Nucleoside analogs as antiviral compounds are justified by the high probability of their absorption by human cells and incorporation into nucleic acids. This can block nucleic acid synthesis by preventing the incorporation of new nucleosides into the growing RNA strand inhibiting crucial processes of cell metabolism, such as cell division and, in the case of virus infection, the viral replication process [37].

Two series of ribonucleosides (42–44 and 45–49) were planned by Slusarczyk and co-workers (Figure 4), and the latter was based on the ProTide technology developed by McGuigan to improve the activity and to overcome resistance through the introduction of an amino acid ester and two lipophilic and biolabile groups linked to the phosphate group of the molecule, optimizing their membrane permeability and thus avoiding the need for nucleoside transporters [37]. Pyrimidine and its analogs may be involved in the inhibition of the host’s intracellular enzyme orotidine-5′-monophosphate decarboxylase rather than acting against specific viral enzymes, and this may explain why most of the compounds tested in the cytopathic-based assay in Vero cells did not exhibit antiviral activity against CHIKV (EC₅₀ > 200 μM; Table 3) [37].
On the other hand, β-D-N4-hydroxycytidine (50) exhibited good antiviral activity against CHIKV at a lower concentration than favipiravir (2) (EC50 = 0.2 µM), which was used as the gold standard for both the Asian and African CHIKV strains. It was suggested that its performance occurs via the inhibition of the initial negative-stranded RNA synthesis or through chain termination or mutagenesis, which can, in turn, interfere with the correct formation of the replicase complex. The fact is that CHIKV replication was remarkably inhibited by this compound. The calculated CC50 of compound 50 was 7.7 µM in Vero cells, which is at least 38 times higher than its EC50. The cytotoxicity of 50 changes drastically according to cell line used in the assay, for peripheral blood mononuclear cells (PBMCs) it was 30.6 µM and for lymphoblastic cells originally derived from a child with acute lymphoblastic leukemia (CEM), it was 2.5 µM. In all cases, the CC50 was at least 10 times higher than the EC50 (Table 3) [38].

**Table 3. Anti-CHIKV activity of the ribonucleoside derivatives.**

| Reference                  | Compound | CC50 (µM) | EC50 (µM) |
|----------------------------|----------|-----------|-----------|
| Standard (5)               |          | >10       | 0.468     |
| 42                         |          | 47.02     | >200      |
| 43                         |          | 9.04      | >200      |
| 44                         |          | >200      | >200      |
| 45                         |          | 81.80     | >200      |
| 46                         |          | >200      | >200      |
| 47                         |          | 81.29     | >200      |
| 48                         |          | >200      | >200      |
| 49                         |          | 53.10     | >50       |
| Slusarczyk (2018) [37]     | 50       | 30.6<sup>c</sup> | 0.2<sup>a,b</sup> |
|                            |          | 7.7<sup>d</sup> |           |
|                            |          | 2.5<sup>e</sup> |           |
| Ehteshami (2016) [38]      | Standard (2) | ND | 0.3<sup>a</sup> |
|                            |          |           | 0.6<sup>b</sup> |

<sup>a</sup> = CHIKV infectious model (Asian); <sup>b</sup> = CHIKV infectious model East/Central/South African 2006 (ECSA); <sup>c</sup> = peripheral blood mononuclear cells; <sup>d</sup> = Vero cells; <sup>e</sup> = CEM cells.

### 3.4. Piperazinyl–Pyrimidine Derivatives

The piperazinyl–pyrimidine derivatives (52–62) were planned by optimization of the compound 51, which was identified by high-throughput screening by the Center for Innovation and Stimulation of Drug Discovery and by the University of Leuven [9]. To optimize compound 51, systematic structural variations (shown in Figure 5) were performed in its structure, which was divided into five parts to achieve an increase in antiviral activity and a decrease in cytotoxicity. For group A (modifications on, or replacement of, the 4-fluorophenyl ring), compounds 53, 54 and 55 can be highlighted since all these compounds were more active than the standard 51 (Table 4). Chlorine-substituted 53 gave the best result with an EC50 of 5 µM, and iodine-substituted 55 (EC50 of 5.9 µM) and bromine-substituted 54 (EC50 = 7.1 µM) were less active than 53. In order to assess the influence...
of the sulfonamide linker, group B was designed to replace it with an amide (58) or a methyl group (59). Both compounds were more than twice as potent as 51, derivative 58 had an EC\(_{50}\) of 4 \(\mu\)M, and 59 had an EC\(_{50}\) of 2.5 \(\mu\)M. Substituents of the piperazine linker (Group C) were introduced to investigate the function of this group, and the results showed that the prepared analog (60) was less active (EC\(_{50}\) of 16 \(\mu\)M) than 51. Therefore, according to the authors, 1,4-piperazine was the better choice to reach a potent antiviral activity [9]. For group D, the replacement of the ethylamine side chain with isopropylamine provided derivative 61, which demonstrated good activity (EC\(_{50}\) of 9.5 \(\mu\)M) against CHIKV compared to compound 51. However, this result was also accompanied by increased cytotoxicity (CC\(_{50}\) = 66.4 \(\mu\)M), indicating that the ethylamine side chain is essential for antiviral activity. Finally, in group E, we investigated whether the methyl group as a substituent on the pyrimidine ring is essential or not for the antiviral activity. The results showed that derivative 62 also demonstrated good activity (EC\(_{50}\) of 3.2 \(\mu\)M) against CHIKV compared to 51. Nevertheless, the cytotoxicity of this compound was increased (Table 4) [9].

![Figure 5. Piperazinyl–pyrimidine analogs (51–62) as inhibitors of Chikungunya virus.](image)

| Compound | CC\(_{50}\) (\(\mu\)M) | EC\(_{50}\) (\(\mu\)M) |
|----------|----------------|------------------|
| Standard (51) | 122 ± 24 | 8.7 ± 1 |
| 52 | 156 ± 35 | 14 ± 3 |
| 53 | 51 ± 19 | 5 ± 0.4 |
| 54 | 44 ± 19 | 7.1 ± 0.01 |
| 55 | 19 ± 2 | 5.9 ± 0.2 |
| 56 | 95 ± 74 | 15 ± 2 |
| 57 | 181 ± 0.4 | 10 ± 0.2 |
| 58 | >260 | 4.0 ± 1 |
| 59 | 69 ± 7 | 2.5 ± 1 |
| 60 | 106 ± 69 | 16 ± 1 |
| 61 | 66.4 ± 6 | 9.5 ± 2 |
| 62 | 59 ± 18 | 3.2 ± 0.2 |
3.5. Purine-β-Lactam Hybrids

The combined synthesis of purines and β-lactams has emerged as a new and relevant strategy in drug discovery programs. Both nitrogen heterocyclic nuclei have been a source of inspiration for medicinal chemists for decades resulting in a variety of derivatives with pronounced biological activities. Purine-based antiviral drugs are largely known, for example, acyclovir, which is used for treatment against herpes [56] and abacavir as an anti-HIV drug [57], whereas β-lactam derivatives are found with anti-tumor activity [58] and anti-malarial activity [59], in addition to being able to inhibit HIV-1 protease [60] and cholesterol absorption [61]. Hence, the objective of D’hooghe and co-authors [62] involved the synthesis and antiviral evaluation of purine-β-lactam hybrids and of the corresponding β-lactam ring-opening products (63–65; Figure 6). The synthesized hybrids were screened for their antiviral activity against different viruses, including CHIKV. Moderate activities against CHIKV were registered and these initial screenings revealed that purine derivatives, 63 and 64, were identified as promising lead structures for further study on these scaffolds (Table 5).

![Figure 6. Purine derivatives, 63–65.](image)

**Table 5. Anti-CHIKV activities of purine-β-lactam derivatives, 63–65 [62].**

| Compound | CC₅₀ (µM) | EC₅₀ (µM) | SI |
|----------|-----------|-----------|----|
| 63       | >98.36    | 17.11     | >5.75 |
| 64       | 58.97     | 13.01     | 4.53 |
| 65       | 71.20     | 11.51     | 6.19 |

3.6. Thiazolopyrimidine and Triazolopyrimidine Derivatives

In the last years, new nitrogen-based chemical scaffolds have been identified as potential anti-CHIKV agents. Among them, thiazolidinone fused to a pyrimidine ring has been described as a notable pharmacophore for the development of novel anti-CHIKV scaffolds [39]. Figure 7 summarizes the structure of thiazolopyrimidine derivatives with activity against CHIKV. The pyrimidin-3,5(2H)-dione (71) was the most promising anti-CHIKV compound among the thiazolopyrimidine analogs. This compound was able to inhibit 58% of CHIKV infection at a concentration of 20 µg.mL⁻¹, and the EC₅₀ was determined using logarithmic interpolation. The calculated EC₅₀ of this compound was 42 µM. In addition, three other molecules of this series showed inhibition of CHIKV replication >10% (Table 6) with values of 19%, 28% and 34%, respectively for 66, 68 and 72 [39].
Gigante and co-workers [31] synthesized compound 73, which showed an EC$_{50}$ of 19 ± 2 µM with a CC$_{50}$ > 743 in Vero cells using the CHIKV 899 strain. This triazolopyrimidine derivative 73 and its related compounds 75, 76, 77, 79, 80 and 81 (Figure 8) were able to inhibit the guanylation step performed by the nsP1 protein of Venezuelan equine encephalitis virus (VEEV), suggesting similar activity against CHIKV. Interestingly, the mutation P34S at nsP1 reverted the inhibition promoted by this compound, conferring resistance against it [11,19].

Compound 75 was ten times more potent than compound 73 and six times more potent than compound 74 in studies of Gigante and collaborators [31]. The introduction of oximes in this nucleus showed significant values of EC$_{50}$ = 5.2 ± 0.5 and 6.9 ± 2 µM for derivatives 78 and 80, respectively. Notwithstanding this, the best EC$_{50}$ obtained was 2.6 ± 1 µM for molecule 75 only in the CHIKV 899 strain. On the other hand, the compounds 82–85 proved to be potent selective inhibitors for CHIKV in all five analyzed strains [19,32]. CHIKV Congo 95 strain was the most susceptible to triazolopyrimidines and exhibited an EC$_{50}$ between 0.3 and 1.0 µM to compounds 82–85. For the St. Martin strain, derivatives 82 and 84 had better efficacy results when compared to compounds 73 and 75 (Table 7) [32].
Table 7. Triazolopyrimidine compounds with activity for CHIKV strains [19,31,32].

| Reference          | Compound | SI    | CC50 (µM) | EC50 (µM) | CHIKV 899 | CHIKV Venturini | CHIKV Congo 95 | CHIKV St. Martin | CHIKV OPY | CHIKV nsP1-P34S |
|--------------------|----------|-------|-----------|-----------|-----------|-----------------|-----------------|-----------------|-----------|-----------------|
| Gigante (2014) [31]| 73       | 39 ± 5| >743      | 19 ± 2    | 26 ± 2    | 6.35 ± 0.05     | 23.9 ± 0.5      | 28              | 116 ± 60  | ND              |
|                    | 74       | ND    | >704      | 12 ± 4    | ND        | ND              | ND              | ND              | ND        | ND              |
|                    | 75       | 64    | >668 [31] | 3 ± 1     | 1.43 ± 0.01 | 0.75 ± 0.35 | 2.9 ± 0.05 | 2.6 ± 0.5 | >167      |
| Gigante (2017) [19]| 76       | 101 ± 73 | 3.6 ± 1.3 | 5.2 ± 0.2 | 1.1 ± 0.1 | 4.2 ± 0.8 | ND            | ND            | ND        | ND              |
|                    | 77       | >729  | 12 ± 1    | 6.7       | 2.5       | ND             | ND             | ND              | ND        | ND              |
|                    | 78       | 162 ± 1 | 5.2 ± 0.5 | ND        | ND        | ND             | ND             | ND              | ND        | ND              |
|                    | 79       | 165 ± 8 | 16 ± 6    | ND        | ND        | ND             | ND             | ND              | ND        | ND              |
|                    | 80       | 95 ± 40 | 6.9 ± 2   | 9.6 ± 1.2 | 3.0 ± 0.5 | 14 ± 3.5 | ND            | ND            | ND        | ND              |
|                    | 81       | 166 ± 26 | 16 ± 1.8  | ND        | ND        | ND             | ND             | ND              | ND        | ND              |
| Gómez-Sanjuan (2018) [32]| 82       | 70    | 84 ± 19   | 1.2 ± 0.01 | 1.65 ± 0.5 | 0.3 ± 0.0 | 2 ± 0.3 | ND            | ND        | ND              |
|                    | 83       | 18    | 59 ± 23   | 3.2 ± 1.0 | 2.6 ± 1.1 | 1 ± 0.1 | ND        | ND             | ND        | ND              |
|                    | 84       | >147  | >220      | 1.5 ± 0.3 | 1.2 ± 0.2 | 0.35 ± 0.5 | 1.2 ± 0.5 | 3.4 ± 1.2 | ND        |
|                    | 85       | 23    | 201 ± 26  | 8.9 ± 6.1 | 2.9 ± 0.4 | 1.0 ± 0.4 | 3 ± 2.5 | 5.4 ± 2.4 | 23 ± 14  |
| Standard: Chloroquine | 8.1      | 89 ± 28 | 11 ± 7    | ND        | ND        | ND             | ND             | ND              | ND        | ND              |
4. Conclusions

The purpose of this review was to provide a significant insight into the development of new nitrogen-based heterocyclic antiviral compounds against CHIKV and their likely mechanisms of action in order to guide our knowledge toward compound optimization. The reviewed molecules could act on several targets, such as enzymes and pathways that are essential for entry, survival, and viral infection; however, interactions with cellular proteins can cause greater cytotoxicity, and this work provided new biological perspectives based on the analysis of the relationship between structure and its activity. It is still necessary to emphasize that the studies were carried out in silico and in vitro, necessitating the future exploration of the potential of application of pyrimidines and their derivatives in vivo followed by clinical trials to develop effective antiviral treatments. Analysis of active antivirals and their beneficial effects in chronic infections of the joints and a possible prophylactic use for travelers and residents of endemic areas will be necessary. The information on molecules presented in this work could be used as the basis for planning new classes of CHIKV inhibitors with expressive selectivity for other pharmacological targets and to identify their mechanisms of action to obtain new antiviral drugs.

Author Contributions: A.C.S., R.C.S.F., J.C.J.M.D.S.M., D.A. and V.R.C. conceived, discussed and wrote the review. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We acknowledge Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) (APQ1 E-26/10.002205/2016 for V.R.C), CNPq, CAPES, and UFF (FOPESQ-2020) for financial support and research fellowships.

Conflicts of Interest: The authors declared no conflict of interest.

References

1. Burt, F.J.; Chen, W.; Miner, J.J.; Lenschow, D.J.; Merits, A.; Schnettler, E.; Kohl, A.; Rudd, P.A.; Taylor, A.; Herrero, L.J.; et al. Chikungunya virus: An update on the biology and pathogenesis of this emerging pathogen. Lancet Infect. Dis. 2017, 17, e107–e117. [CrossRef]
2. Robinson, M.C. An Epidemic Of Virus Disease In Southern Province, Tanganyika Territory, In 1952-53. Trans. R. Soc. Trop. Med. Hyg. 1955, 49, 28–32. [CrossRef]
3. Ghildiyal, R.; Gabrani, R. Antiviral therapeutics for chikungunya virus. Expert Opin. Ther. Pat. 2020, 30, 467–480. [CrossRef] [PubMed]
4. Tsetsarkin, K.A.; Chen, R.; Leal, G.; Forrester, N.; Higgs, S.; Huang, J.; Weaver, S.C. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc. Natl. Acad. Sci. USA 2011, 108, 7872–7877. [CrossRef] [PubMed]
5. Zeller, H.; Van Bortel, W.; Sudre, B. Chikungunya: Its history in Africa and Asia and its spread to new regions in 2013–2014. Proc. J. Infect. Dis. 2016, 214, 5436–5440. [CrossRef] [PubMed]
6. Centre, E.; Prevention, D. Chikungunya Worldwide Overview; ECDC: Solna, Sweden, 2020.
7. Azevedo, R.D.S.D.S.; Oliveira, C.S.; Vasconcelos, P.F.D.C. Chikungunya risk for Brazil. Rev. Saude Publica 2015, 49. [CrossRef]
8. da Cunha, R.V.; Trinta, K.S. Chikungunya virus: Clinical aspects and treatment. Mem. Inst. Oswaldo Cruz 2017, 112, 523–531. [CrossRef] [PubMed]
9. Moesslacher, J.; Battisti, V.; Delang, L.; Neyts, J.; Abdelnabi, R.; Pürstinger, G.; Urban, E.; Langer, T. Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus. ACS Med. Chem. Lett. 2020, 11, 906–912. [CrossRef] [PubMed]
10. Albulescu, I.C.; White-Scholten, L.; Tas, A.; Hoornweg, T.E.; Ferla, S.; Kovacikova, K.; Smit, J.M.; Brancale, A.; Snijder, E.J.; van Hemert, M.J. Suramin inhibits chikungunya virus replication by interacting with virions and blocking the early steps of infection. Viruses 2020, 12, 314. [CrossRef] [PubMed]
11. Delang, L.; Li, C.; Tas, A.; Quérat, G.; Albulescu, I.C.; De Burghgraeve, T.; Segura Guerrero, N.A.; Gigante, A.; Piorkowski, G.; Decroly, E.; et al. The viral capping enzyme nsP1: A novel target for the inhibition of chikungunya virus infection. Sci. Rep. 2016, 6, 3189. [CrossRef]
12. da Silva-Júnior, E.F.; Leoncini, G.O.; Rodrigues, É.E.S.; Aquino, T.M.; Araújo-Júnior, J.X. The medicinal chemistry of Chikungunya virus. Bioorg. Med. Chem. 2017, 25, 4219–4244. [CrossRef] [PubMed]
13. Hitakarun, A.; Khongwichit, S.; Wikan, N.; Roytrakul, S.; Yoksan, S.; Rajakam, S.; Davidson, A.D.; Smith, D.R. Evaluation of the antiviral activity of orlistat (tetrahydrorlipstatin) against dengue virus, Japanese encephalitis virus, Zika virus and chikungunya virus. Sci. Rep. 2020, 10, 1499. [CrossRef] [PubMed]
14. Cirne-Santos, C.C.; de Barros, C.S.; Nogueira, C.C.R.; Azevedo, R.C.; Yamamoto, K.A.; Meira, G.L.S.; de Vasconcelos, Z.F.M.; Rateliffe, N.A.; Teixeira, V.L.; Schmidt-Chanasit, J.; et al. Inhibition by marine alga of chikungunya virus isolated from patients in a recent disease outbreak in rio de janeiro. *Front. Microbiol.* **2019**, *10*, 2426. [CrossRef][PubMed]

15. Solignat, M.; Gay, B.; Higgs, S.; Briant, L.; Devaux, C. Replication cycle of chikungunya: A re-emerging arbovirus. *Virology* **2009**, *393*, 183–197. [CrossRef]

16. Strauss, J.H.; Strauss, E.G. The alphaviruses: Gene expression, replication, and evolution. *Microbiol. Rev.* **1994**, *58*, 491–562. [CrossRef]

17. Powers, A.M. Vaccine and therapeutic options to control chikungunya virus. *Clin. Microbiol. Rev.* **2018**, *31*, e00104-16. [CrossRef]

18. Feibelman, K.M.; Fuller, B.P.; Li, L.; LaBarbera, D.V.; Geiss, B.J. Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA polymerase. *Antivir. Res.* **2015**, *144*, 124–131. [CrossRef]

19. Gigante, A.; Gómez-SanJuan, A.; Delang, L.; Li, C.; Bueno, O.; Gamo, A.M.; Priego, E.M.; Camarasa, M.J.; Jochmans, D.; Leyssen, P.; et al. Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against chikungunya virus targeting the viral capping nsP1. *Antivir. Res.* **2017**, *144*, 216–222. [CrossRef]

20. Utt, A.; Das, P.K.; Varjak, M.; Lulla, V.; Lulla, A.; Merits, A. Mutations Conferring a Noncytotoxic Phenotype on Chikungunya Virus Replicons Compromise Enzymatic Properties of Nonstructural Protein 2. *J. Virol.* **2015**, *89*, 3145–3162. [CrossRef]

21. Bhakat, S.; Soliman, M.E.S. Chikungunya virus (CHIKV) inhibitors from natural sources: A medicinal chemistry perspective. *J. Nat. Med.* **2015**, *69*, 451–452. [CrossRef]

22. Campagnola, G.; McDonald, S.; Beaucourt, S.; Vignuzzi, M.; Peersen, O.B. Structure-Function Relationships Underlying the Replication Fidelity of Virus RNA-Dependent RNA Polymerases. *J. Virol.* **2015**, *89*, 275–286. [CrossRef][PubMed]

23. Kovacikova, K.; Morren, B.M.; Tas, A.; Albulescu, I.C.; Van Rijswijk, R.; Jarhad, D.B.; Shin, Y.S.; Jang, M.H.; Kim, G.; Lee, H.W.; et al. 6′-β-fluoro-homoneplanocin A are potent inhibitors of Chikungunya virus replication through their direct effect on viral nonstructural protein 1. *Antimicrob. Agents Chemother.* **2020**, *64*, e02532-19. [CrossRef][PubMed]

24. Ekins, S.; Lane, T.R.; Madrid, P.B. Tilorone: A Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond. *Pharm. Res.* **2020**, *37*, 71. [CrossRef][PubMed]

25. Ferreira, A.C.; Reis, P.A.; de Freitas, C.S.; Sacramento, C.Q.; Hoelz, L.V.B.; Bastos, M.M.; Mattos, M.; Rocha, N.; de Azevedo Quintanilha, I.G.; da Silva Gouveia Pedrosa, C.; et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. *Antimicrob. Agents Chemother.* **2019**, *63*, e0389-18. [CrossRef]

26. Brielant, S.; Garin, D.; Scaramozzin, N.; Jouan, A.; Crance, J.M. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: Synergistic effect of interferon-α and ribavirin combination. *Antivir. Res.* **2004**, *61*, 111–117. [CrossRef]

27. Ozden, S.; Lucas-Hourani, M.; Ceccaldi, P.E.; Basak, A.; Valentine, M.; Benjannet, S.; Hamelin, J.; Jacob, Y.; Mamchaoui, K.; Moully, V.; et al. Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: Impairment of the maturation of the E2 surface glycoprotein. *J. Biol. Chem.* **2008**, *283*, 21899–21908. [CrossRef]

28. Delogu, I.; Pastorino, B.; Baronti, C.; Nougaiède, A.; Bonnet, E.; de Lampasserie, X. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. *Antivir. Res.* **2011**, *90*, 99–107. [CrossRef]

29. Pohjala, L.; Utt, A.; Varjak, M.; Lulla, A.; Merits, A.; Ahola, T.; Tammela, P. Inhibitors of aliphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. *J. Virol.* **2019**, *96*, 183–197. [CrossRef]

30. Kaur, P.; Chu, J.J.H. Chikungunya virus: An update on antiviral development and challenges. *Drug Discov. Today* **2013**, *18*, 969–983. [CrossRef]

31. Gigante, A.; Canela, M.D.; Delang, L.; Priego, E.M.; Camarasa, M.J.; Querat, G.; Neyts, J.; Leyssen, P.; Pérez-Pérez, M.J. Identification of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as novel inhibitors of chikungunya virus replication. *J. Med. Chem.* **2014**, *57*, 4000–4008. [CrossRef]

32. Gómez-SanJuan, A.; Gamo, A.M.; Delang, L.; Pérez-Sánchez, A.; Amrun, S.N.; Abdelnabi, R.; Jacobs, S.; Priego, E.M.; Camarasa, M.J.; Jochmans, D.; et al. Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones. *ACS Infect. Dis.* **2018**, *4*, 605–619. [CrossRef][PubMed]

33. Tánase, C.I.; Drăghici, C.; Hangaru, A.; Pintilie, L.; Maganu, M.; Volobueva, A.; Singegubova, E.; Zarubaev, V.V.; Neyts, J.; Jochmans, D.; et al. New HSV-1 anti-viral 10-homocarbocyclic nucleoside analogs with an optically active substituted bicyclo[2.2.1]heptane fragment as a glycoside moiety. *Molecules* **2019**, *24*, 2446. [CrossRef][PubMed]

34. Hwu, J.R.; Kapoor, M.; Tsay, S.C.; Lin, C.C.; Hwang, K.C.; Horng, J.C.; Chen, I.C.; Shieh, F.K.; Leyssen, P.; Neyts, J. Benzoucaril-coumarin-arene conjugates as inhibiting agents for chikungunya virus. *Antivir. Res.* **2015**, *118*, 103–109. [CrossRef]

35. Shin, Y.S.; Jarhad, D.B.; Jang, M.H.; Kovacikova, K.; Kim, G.; Yoon, J.S.; Kim, H.R.; Hyun, Y.E.; Tippins, A.S.; Chang, T.S.; et al. Identification of 6′-β-fluoro-homoaristeromycin as a potent inhibitor of chikungunya virus replication. *Eur. J. Med. Chem.* **2020**, *199*, [CrossRef][PubMed]

36. Yoon, J.S.; Kim, G.; Jarhad, D.B.; Kim, H.R.; Shin, Y.S.; Qiu, S.; Sahu, P.K.; Kim, H.O.; Lee, H.W.; Wang, S.B.; et al. Design, Synthesis, and Anti-RNA Virus Activity of 6′-Fluorinated-Aristeromycin Analogues. *J. Med. Chem.* **2019**, *62*, 6346–6362. [CrossRef][PubMed]

37. Slusarczyk, M.; Ferla, S.; Brancale, A.; McGuigan, C. Synthesis and Biological Evaluation of 6-Substituted-5-Fluourouridine ProTides. *Bioorg. Med. Chem.* **2018**, *26*, 551–565. [CrossRef][PubMed]
38. Ehteshami, M.; Tao, S.; Zandi, K.; Hsiao, H.M.; Jiang, Y.; Hammond, E.; Amblard, F.; Russell, O.O.; Merits, A.; Schinazi, R.F. Characterization of β-D-N4-hydroxycytidine as a novel inhibitor of Chikungunya virus. *Antimicrob. Agents Chemother.* **2017**, *61*, [CrossRef] [PubMed]

39. Fares, M.; McCosker, P.M.; Alsherbiny, M.A.; Willis, A.C.; Clark, T.; Neyts, J.; Jochmans, D.; Keller, P.A. Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-α]pyrimidines as potential anti-chikungunya agents. *RSC Adv.* **2020**, *10*, 5191–5195. [CrossRef]

40. Goh, V.S.L.; Mok, C.K.; Chu, J.J.H. Antiviral natural products for arbovirus infections. *Molecules* **2020**, *25*, 2796. [CrossRef]

41. Jain, J.; Kumar, A.; Narayanan, V.; Ramasamy, R.S.; Sathiyaarajasewaran, P.; Shree Devi, M.S.; Kannan, M.; Sunil, S. Antiviral activity of ethanolic extract of Nilavembu Kudineer against dengue and chikungunya virus through in vitro evaluation. *J. Ayurveda Integr. Med.* **2020**, *11*, 329–335. [CrossRef]

42. Mishra, S.; Pandey, A.; Manvati, S. Coumarin: An emerging antiviral agent. *Heliyon* **2020**, *6*, e03217. [CrossRef] [PubMed]

43. Louvet, M.S.; Gault, G.; Lefebvre, S.; Popowycz, F.; Boulven, M.; Besse, S.; Benoit, E.; Lattard, V.; Grancher, D. Comparative inhibitory effect of prenylated coumarins, ferulonol and ferprecin, contained in the “poisonous chemotype” of Ferula communis on mammal liver microsomal VKORC1 activity. *Phytochemistry* **2015**, *118*, 124–130. [CrossRef] [PubMed]

44. Menezes, J.C.M.D.S.; Diederich, M. Translational role of natural coumarins and their derivatives as anticancer agents. *Future Med. Chem.* **2019**, *11*, 1057–1082. [CrossRef] [PubMed]

45. Osman, H.; Yusufzai, S.K.; Khan, M.S.; Abd Razik, B.M.; Sulaiman, O.; Mohamad, S.; Gansau, J.A.; Ezzat, M.O.; Parumasivam, T.; Hassan, M.Z. New thiazoloyl-coumarin hybrids: Design, synthesis, characterization, X-ray crystal structure, antibacterial and antiviral evaluation. *J. Mol. Struct.* **2018**, *1166*, 147–154. [CrossRef]

46. Márquez, N.; Sancho, R.; Bedoya, L.M.; Alcami, J.; López-Pérez, J.L.; San Feliciano, A.; Fiebich, B.L.; Muñoz, E. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kB pathway. *Antivir. Res.* **2005**, *66*, 137–145. [CrossRef]

47. Peng, H.K.; Chen, W.C.; Lee, J.C.; Yang, S.Y.; Tzeng, C.C.; Lin, Y.T.; Yang, S.C. Novel anilinocoumarin derivatives as agents against hepatitis C virus by the induction of IFN-mediated antiviral responses. *Org. Biomol. Chem.* **2013**, *11*, 1858–1866. [CrossRef]

48. Yusufzai, S.K.; Osman, H.; Khan, M.S.; Abd Razik, B.M.; Ezzat, M.O.; Mohamad, S.; Sulaiman, O.; Gansau, J.A.; Parumasivam, T. 4-Thiazolidinone coumarin derivatives as two-component NS2B/NS3 DENV flavivirus serine protease inhibitors: Synthesis, molecular docking, biological evaluation and structure–activity relationship studies. *Chem. Cent. J.* **2018**, *12*, 69. [CrossRef]

49. Hwu, J.R.; Singha, R.; Hong, S.C.; Chang, Y.H.; Das, A.R.; Vliegen, I.; De Clercq, E.; Neyts, J. Synthesis of new benzimidazolocoumarin conjugates as anti-hepatitis C virus agents. *Antivir. Res.* **2008**, *77*, 157–162. [CrossRef]

50. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y.H.; Das, A.R.; Chakraborty, S.K.; Hong, S.C.; Tsay, S.C.; Hsu, M.H.; Hwu, J.R. Structure-activity relationship of new anti-hepatitis C virus agents: Heterocycle-coumarin conjugates. *J. Med. Chem.* **2009**, *52*, 1486–1490. [CrossRef]

51. Hwu, J.R.; Lin, S.Y.; Tsay, S.C.; De Clercq, E.; Leysen, P.; Neyts, J. Coumarin-purine ribofuranoside conjugates as new agents against hepatitis C virus. *J. Med. Chem.* **2011**, *54*, 2114–2126. [CrossRef]

52. Rashamuse, T.J.; Klein, R.; Kaye, P.T. Synthesis of Baylis-Hillman-derived phosphonated 3-(benzylaminomethyl) coumarins. *Synth. Commun.* **2010**, *40*, 3683–3690. [CrossRef]

53. Thaisrivongs, S.; Tomich, P.K.; Watempaugh, K.D.; Chong, K.T.; Howe, J.W.; Yang, C.P.; Strohbach, J.W.; Turner, S.R.; McGrath, J.P.; Bohanon, M.J.; et al. Structure-Based Design of HIV Protease Inhibitors: 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Non-peptidic Inhibitors. *J. Med. Chem.* **1994**, *37*, 3200–3204. [CrossRef] [PubMed]

54. Hwu, J.R.; Huang, W.C.; Lin, S.Y.; Tan, K.T.; Hu, Y.C.; Shieh, F.K.; Bachurin, S.O.; Ustyugov, A.; Tsay, S.C. Chikungunya virus inhibition by synthetic coumarin–guanosine conjugates. *Eur. J. Med. Chem.* **2019**, *166*, 136–143. [CrossRef] [PubMed]

55. Wang, H.L.; O’Rear, J.; Stollar, V. Mutagenesis of the Sindbis virus nsP1 protein: Effects on methyltransferase activity and viral infectivity. *Virology* **1996**, *228*, 339–345. [CrossRef]

56. De Clercq, E. In search of selective antiviral chemotherapy. *Clin. Microbiol. Rev.* **1997**, *10*, 674–693. [CrossRef]

57. Balzarini, J.; Aquaro, S.; Hassan-Abdallah, A.; Daluge, S.M.; Perno, C.F.; McGuigan, C. Improved antiviral activity of the arylxymethylxanlynyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carboxib 5′-triphosphate metabolites. *FEBS Lett.* **2004**, *573*, 38–44. [CrossRef]

58. Veinberg, G.; Shestakova, I.; Vorona, M.; Kanepe, I.; Lukevics, E. Synthesis of antitumor 6-alkylidenepenicillanate sulfones and related 3-alkylidene-2-azetidinones. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 147–150. [CrossRef]

59. Niwarsarka, M.; Thavaselvam, D.; Prasanna, S.; Sharma, M.; Kaushik, M.P. Design, synthesis and biological evaluation of novel bicyclic β-lactams as potential antimarialars. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1371–1373. [CrossRef]

60. Sperka, T.; Pitišek, J.; Bagossi, P.; Tözsér, J. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3086–3090. [CrossRef]

61. Kvænne, L.; Werder, M.; Hauser, H.; Carreira, E.M. Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption. *J. Med. Chem.* **2005**, *48*, 6035–6053. [CrossRef] [PubMed]

62. D’hooghe, M.; Mollet, K.; De Vreese, R.; Jonckers, T.H.M.; Dams, G.; De Kimpe, N. Design, Synthesis, and Antiviral Evaluation of Purine-β-lactam and Purine-aminopropanol Hybrids. *J. Med. Chem.* **2012**, *55*, 5637–5641. [CrossRef] [PubMed]